Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Buy” from Brokerages

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSGet Rating) has been assigned a consensus rating of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.14.

Several analysts have recently issued reports on the stock. Cantor Fitzgerald boosted their price target on shares of Marinus Pharmaceuticals from $25.00 to $28.00 in a research report on Wednesday, April 20th. Truist Financial increased their target price on shares of Marinus Pharmaceuticals from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, March 22nd. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, March 22nd. SVB Leerink lowered their price objective on Marinus Pharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 22nd. Finally, JMP Securities lifted their price objective on Marinus Pharmaceuticals from $21.00 to $22.00 and gave the company a “market outperform” rating in a research note on Tuesday, March 22nd.

A number of large investors have recently bought and sold shares of the stock. Walleye Capital LLC bought a new stake in Marinus Pharmaceuticals during the fourth quarter worth about $125,000. Nisa Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals during the first quarter worth about $150,000. Invesco Ltd. lifted its stake in Marinus Pharmaceuticals by 24.6% during the third quarter. Invesco Ltd. now owns 14,644 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 2,889 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in Marinus Pharmaceuticals by 40.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 15,932 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 4,597 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Marinus Pharmaceuticals by 63.8% during the first quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 7,928 shares during the last quarter. 80.89% of the stock is owned by institutional investors.

Shares of NASDAQ MRNS traded down $0.17 during midday trading on Monday, hitting $5.49. The company’s stock had a trading volume of 323,237 shares, compared to its average volume of 311,266. The stock has a fifty day moving average price of $7.89 and a 200 day moving average price of $9.87. Marinus Pharmaceuticals has a one year low of $4.19 and a one year high of $19.83. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $203.21 million, a price-to-earnings ratio of -2.22 and a beta of 1.49.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last posted its quarterly earnings results on Monday, March 21st. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.04. Marinus Pharmaceuticals had a negative net margin of 328.21% and a negative return on equity of 127.49%. The company had revenue of $1.52 million for the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the previous year, the firm posted ($0.55) earnings per share. On average, equities research analysts predict that Marinus Pharmaceuticals will post -2.59 earnings per share for the current fiscal year.

About Marinus Pharmaceuticals (Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Articles

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.